The Pharmaceutical Research Institute, Albany College of Pharmacy and Health Sciences, Rensselaer, NY, USA.
The Pharmaceutical Research Institute, Albany College of Pharmacy and Health Sciences, Rensselaer, NY, USA; Department of Physiology, Veterinary Medicine Faculty, Uludag University, Gorukle, Bursa, Turkey.
Cancer Lett. 2014 Aug 1;350(1-2):25-33. doi: 10.1016/j.canlet.2014.04.016. Epub 2014 Apr 24.
Sulfated non-anticoagulant heparins (S-NACHs) might be preferred for potential clinical use in cancer patients without affecting hemostasis as compared to low molecular weight heparins (LMWHs). We investigated anti-tumor effects, anti-angiogenesis effects, and mechanisms of S-NACH in a mouse model of pancreatic cancer as compared to the LMWH tinzaparin. S-NACH or tinzaparin with or without gemcitabine were administered, and tumor luminescent signal intensity, tumor weight, and histopathology were assessed at the termination of the study. S-NACH and LMWH efficiently inhibited tumor growth and metastasis, without any observed bleeding events with S-NACH as compared to tinzaparin. S-NACH distinctly increased tumor necrosis and enhanced gemcitabine response in the mouse pancreatic cancer models. These data suggest the potential implication of S-NACH as a neoadjuvant in pancreatic cancer.
硫酸化非抗凝肝素（S-NACH）可能比低分子量肝素（LMWH）更适合在癌症患者中用于潜在的临床应用，而不会影响止血。我们研究了 S-NACH 与 LMWH 亭扎肝素相比在胰腺癌小鼠模型中的抗肿瘤作用、抗血管生成作用和机制。在研究结束时，评估了 S-NACH 或亭扎肝素加或不加吉西他滨的肿瘤发光信号强度、肿瘤重量和组织病理学。S-NACH 和 LMWH 有效地抑制了肿瘤生长和转移，与亭扎肝素相比，S-NACH 没有观察到任何出血事件。S-NACH 明显增加了小鼠胰腺癌模型中的肿瘤坏死，并增强了吉西他滨的反应。这些数据表明 S-NACH 作为胰腺癌新辅助治疗的潜在意义。
